

JCO6 Rec'd PCT/PTO 15 SEP 2005

PATENT

ATTORNEY DOCKET NO. 50026/054001

Certificate of Mailing: Date of Deposit: September 13, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hamada et al.	Art Unit:	Not Yet Assigned
Serial No.:	10/546,000	Examiner:	Not Yet Assigned
Filed:	August 18, 2005	Customer No.:	21559
Title:	METHODS FOR TREATING ISCHEMIC DISEASES		

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed with the exception of U.S. patents, U.S. patent application publications, and those noted herein.

The present application is the U.S. national stage of PCT/JP2004/000957. A copy of the corresponding International Search report was submitted in the present application on August 18, 2005. Under M.P.E.P. (Eighth Edition, August 2001 (Revision 2, May 2004)) § 1893.03(g), Applicants note that because the International Search for PCT/JP2004/000957 was conducted by the Japanese Patent Office, copies of the

documents cited in the International Search Report should have been provided to the U.S.P.T.O. Therefore, copies of the following references are not enclosed.

WO 97/27310 A1

WO 02/100441 A2

Hattori et al., "Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells," *J. Exp. Med.* 193(9):1005-1014 (2001).

Takahashi et al., "Adenoviral-Delivered Angiopoietin-1 Reduces the Infarction and Attenuates the Progression of Cardiac Dysfunction in Rat Model of Acute Myocardial Infarction," *Mol. Ther.* 8(4):584-592 (2003).

Takakura et al., "A Role for Hematopoietic Stem Cells In Promoting Angiogenesis," *Cell* 102(2):199-209 (2000).

Further, WO 02/100441 A2 is written in the Japanese language. An English translation of this reference is enclosed.

Suda, "Angiogenesis and Clinical Application," *Experimental Medicine* 19(7):826-829 (2001), which is written in the Japanese language, is enclosed. A concise explanation of the relevance of this reference is provided in accordance with 37 C.F.R. § 1.98(a)(3)(i).

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 13 September 2005



James D. DeCamp, Ph.D.

Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

JAN N. TITTEZ, Ph.D.  
Reg. No. 52,290

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No. 50026/054001 Serial No. 10/546,000 Applicant Hamada et al. Filing Date August 18, 2005 Group Not Yet Assigned IDS Filed September 13, 2005				
U.S. PATENTS OR PUBLISHED APPLICATIONS						
Examiner's Initials	Patent or Publication Number	Issue or Publication Date	Applicant/Patentee	Class	Subclass	Filing Date (If Appropriate)
	2004-0234502 A1	Nov. 25, 2004	Hamada et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 97/27310 A1	Jul. 31, 1997	WIPO			
	WO 02/100441 A2	Dec. 19, 2002	WIPO			Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Asahara et al., "Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced Postnatal Neovascularization," <i>Circ. Res.</i> 83(3):233-240 (1998).					
	Banai et al., "Upregulation of Vascular Endothelial Growth Factor Expression Induced by Myocardial Ischaemia: Implications for Coronary Angiogenesis," <i>Cardiovasc. Res.</i> 28(8):1176-1179 (1994).					
	Baumgartner et al., "Constitutive Expression of phVEGF <sub>165</sub> after Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia," <i>Circulation</i> 97(12):1114-1123 (1998).					
	Baumgartner et al., "Lower-Extremity Edema Associated with Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor," <i>Ann. Intern. Med.</i> 132(11):880-884 (2000).					
	Berse et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene Is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," <i>Mol. Biol. Cell</i> 3(2):211-220 (1992).					
	Carmeliet, "VEGF Gene Therapy: Stimulating Angiogenesis or Angioma-Genesis?" <i>Nat. Med.</i> 6(10):1102-1103 (2000).					
	Chae et al., "Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization," <i>Arterioscler. Thromb. Vasc. Biol.</i> 20(12):2573-2578 (2000).					
	Hattori et al., "Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells," <i>J. Exp. Med.</i> 193(9):1005-1014 (2001).					
	Isner et al., "Treatment of Thromboangiitis Obliterans (Buerger's Disease) by Intramuscular Gene Transfer of Vascular Endothelial Growth Factor: Preliminary Clinical Results," <i>J. Vasc. Surg.</i> 28(6):964-975 (1998).					
	Ladoux and Frelin, "Hypoxia Is a Strong Inducer of Vascular Endothelial Growth Factor mRNA Expression in the Heart," <i>Biochem. Biophys. Res. Comm.</i> 195(2):1005-1010 (1993).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/054001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/546,000
		Applicant	Hamada et al.
		Filing Date	August 18, 2005
		Group	Not Yet Assigned
		IDS Filed	September 13, 2005
(37 C.F.R. § 1.98(b))			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
Lathi et al., "Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease: Anesthetic Management and Results," <i>Anesth. Analg.</i> 92(1):19-25 (2001).			
Lee et al., "VEGF Gene Delivery to Myocardium: Deleterious Effects of Unregulated Expression," <i>Circulation</i> 102(8):898-901 (2000).			
Li et al., "VEGF, <i>flk-1</i> , and <i>flt-1</i> Expression in a Rat Myocardial Infarction Model of Angiogenesis," <i>Am. J. Physiol.</i> 270(5 Pt. 2):H1803-H1811 (1996).			
Losordo et al., "Gene Therapy for Myocardial Angiogenesis: Initial Clinical Results with Direct Myocardial Injection of phVEGF <sub>165</sub> as Sole Therapy for Myocardial Ischemia," <i>Circulation</i> 98(25):2800-2804 (1998).			
Lubiatowski et al., "Gene Therapy by Adenovirus-Mediated Vascular Endothelial Growth Factor and Angiopoietin-1 Promotes Perfusion of Muscle Flaps," <i>Plast. Reconstr. Surg.</i> 110(1):149-159 (2002).			
Matsuno et al., "Lack of $\alpha$ 2-Antiplasmin Promotes Pulmonary Heart Failure via Overrelease of VEGF after Acute Myocardial Infarction," <i>Blood</i> 100(7):2487-2493 (2002).			
Nykänen et al., "Angiopoietin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis," <i>Circulation</i> 107(9):1308-1314 (2003).			
Rosengart et al., "Angiogenesis Gene Therapy: Phase I Assessment of Direct Intramyocardial Administration of an Adenovirus Vector Expressing VEGF121 cDNA to Individuals with Clinically Significant Severe Coronary Artery Disease," <i>Circulation</i> 100(5):468-474 (1999).			
Schwarz et al., "Evaluation of the Effects of Intramyocardial Injection of DNA Expressing Vascular Endothelial Growth Factor (VEGF) in a Myocardial Infarction Model in the Rat – Angiogenesis and Angioma Formation," <i>J. Am. Coll. Cardiol.</i> 35(5):1323-1330 (2000).			
Seko et al., "Serum Levels of Vascular Endothelial Growth Factor in Patients with Acute Myocardial Infarction Undergoing Reperfusion Therapy," <i>Clin. Sci. (Lond.)</i> 92(5):453-454 (1997).			
Shyu et al., "Direct Intramuscular Injection of Plasmid DNA Encoding Angiopoietin-1 but Not Angiopoietin-2 Augments Revascularization in the Rabbit Ischemic Hindlimb," <i>Circulation</i> 98(19):2081-2087 (1998).			
Shyu et al., "Synergistic Effect of Angiopoietin-1 and Vascular Endothelial Growth Factor on Neoangiogenesis in Hypercholesterolemic Rabbit Model with Acute Hindlimb Ischemia," <i>Life Sci.</i> 73(5):563-579 (2003).			
Siddiqui et al., "Combination of Angiopoietin-1 and Vascular Endothelial Growth Factor Gene Therapy Enhances Arteriogenesis in the Ischemic Myocardium," <i>Biochem. Biophys. Res. Comm.</i> 310(3):1002-1009 (2003).			
Suda, "Angiogenesis and Clinical Application," <i>Experimental Medicine</i> 19(7):826-829 (2001).			
Symes et al., "Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease," <i>Ann. Thorac. Surg.</i> 68(3):830-837 (1999).			
Taichman et al., "Human Neutrophils Secrete Vascular Endothelial Growth Factor," <i>J. Leukoc. Biol.</i> 62(3):397-400 (1997).			
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/054001
		Serial No.	10/546,000
		Applicant	Hamada et al.
		Filing Date	August 18, 2005
		Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed	September 13, 2005
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION			
	Takahashi et al., "Adenoviral-Delivered Angiopoietin-1 Reduces the Infarction and Attenuates the Progression of Cardiac Dysfunction in Rat Model of Acute Myocardial Infarction," <i>Mol. Ther.</i> 8(4):584-592 (2003).		
	Takakura et al., "A Role for Hematopoietic Stem Cells in Promoting Angiogenesis," <i>Cell</i> 102(2):199-209 (2000).		
	Takeshita et al., "Intramuscular Administration of Vascular Endothelial Growth Factor Induces Dose-Dependent Collateral Artery Augmentation in a Rabbit Model of Chronic Limb Ischemia," <i>Circulation</i> 90(5 Part 2):II-228-II-234 (1994).		
	Takeshita et al., "Therapeutic Angiogenesis: A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93(2):662-670 (1994).		
	Thurston et al., "Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1," <i>Science</i> 286(5449):2511-2514 (1999).		
	Thurston et al., "Angiopoietin-1 Protects the Adult Vasculature against Plasma Leakage," <i>Nat. Med.</i> 6(4):460-463 (2000).		
	Thurston, "Complementary Actions of VEGF and Angiopoietin-1 on Blood Vessel Growth and Leakage," <i>J. Anat.</i> 200(6):575-580 (2002).		
	Xu et al., "Expression of Vascular Endothelial Growth Factor and Its Receptors Is Increased, but Microvascular Relaxation Is Impaired in Patients after Acute Myocardial Ischemia," <i>J. Thorac. Cardiovasc. Surg.</i> 121(4):735-742 (2001).		
	Yamashita et al., "Flk1-Positive Cells Derived from Embryonic Stem Cells Serve as Vascular Progenitors," <i>Nature</i> 408(6808):92-96 (2000).		
	Yonemitsu et al., "Characterization of In Vivo Gene Transfer into the Arterial Wall Mediated by the Sendai Virus (Hemagglutinating Virus of Japan) Liposomes: An Effective Tool for the In Vivo Study of Arterial Diseases," <i>Lab. Invest.</i> 75(3):313-323 (1996).		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			